AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. COGT
  4. [Form 4] Cogent Biosciences, Inc. Insider Trading Activity

[Form 4] Cogent Biosciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.

Il modulo Form 4 segnala che la direttrice di Chemours Company (CC), Courtney Mather, ha ricevuto in data 30 giugno 2025 un premio di 2.292 unit脿 azionarie differite (DSU). Ogni DSU corrisponde a una azione ordinaria e verr脿 liquidata nel primo mese successivo all'uscita della direttrice dal consiglio. Il premio 猫 stato registrato a un prezzo di riferimento di 11,45 $ per unit脿. Dopo l'assegnazione, Mather possiede direttamente 2.292 titoli derivati; non sono state comunicate vendite o acquisti aggiuntivi di azioni ordinarie. A parte questa consueta remunerazione per il direttore, la comunicazione non riporta altre transazioni rilevanti o variazioni nella propriet脿.

El formulario Form 4 informa que la directora de Chemours Company (CC), Courtney Mather, recibi贸 el 30 de junio de 2025 un premio de 2,292 unidades de acciones diferidas (DSU). Cada DSU equivale a una acci贸n com煤n y se liquidar谩 en el primer mes despu茅s de que la directora deje la junta. El premio se registr贸 a un precio de referencia de $11.45 por unidad. Tras la concesi贸n, Mather posee directamente 2,292 valores derivados; no se revelaron ventas ni compras adicionales de acciones comunes. Aparte de esta compensaci贸n rutinaria para directores, la presentaci贸n no contiene otras transacciones materiales ni cambios en la propiedad.

Form 4 鞝滌稖靹滌棎 霐半ゴ氅� Chemours Company(CC) 鞚挫偓 Courtney Mather電� 2025雲� 6鞗� 30鞚检棎 2,292臧滌潣 鞚挫棸 欤检嫕 雼渼(DSU)毳� 氚涭晿鞀惦媹雼�. 臧� DSU電� 氤错喌欤� 1欤检棎 頃措嫻頃橂┌, 鞚挫偓臧� 鞚挫偓須岇棎靹� 氍茧煬雮� 頉� 觳� 雼棎 鞝曥偘霅╇媹雼�. 鞚� 靸侅潃 雼渼雼� $11.45鞚� 旮办 臧�瓴╈溂搿� 旮半霅橃棃鞀惦媹雼�. 靾橃棳 鞚错泟 Mather電� 歆侅爲 2,292臧滌潣 韺岇儩 歃濌秾鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 氤错喌欤检棎 雽�頃� 毵る弰雮� 於旉皜 毵れ垬電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞚检儊鞝侅澑 鞚挫偓 氤挫儊 鞕胳棎電� 鞝滌稖靹滌棎 雼るジ 欷戩殧頃� 瓯半灅雮� 靻岇湢甓� 氤�霃� 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Le formulaire Form 4 indique que la directrice de Chemours Company (CC), Courtney Mather, a re莽u le 30 juin 2025 une attribution de 2 292 unit茅s d鈥檃ctions diff茅r茅es (DSU). Chaque DSU 茅quivaut 脿 une action ordinaire et sera r茅gl茅e dans le premier mois suivant le d茅part de la directrice du conseil d鈥檃dministration. Cette attribution est enregistr茅e 脿 un prix de r茅f茅rence de 11,45 $ par unit茅. Apr猫s cette attribution, Mather d茅tient directement 2 292 titres d茅riv茅s ; aucune vente ni achat suppl茅mentaire d鈥檃ctions ordinaires n鈥檃 茅t茅 divulgu茅. En dehors de cette r茅mun茅ration habituelle des administrateurs, le d茅p么t ne contient aucune autre transaction significative ni changement de propri茅t茅.

Das Formular Form 4 berichtet, dass die Direktorin von Chemours Company (CC), Courtney Mather, am 30. Juni 2025 mit 2.292 aufgeschobenen Aktienanteilen (DSUs) ausgezeichnet wurde. Jede DSU entspricht einer Stammaktie und wird im ersten Monat nach dem Ausscheiden der Direktorin aus dem Vorstand ausgeglichen. Die Auszeichnung wurde zu einem Referenzpreis von 11,45 $ pro Einheit verbucht. Nach der Zuteilung besitzt Mather direkt 2.292 derivative Wertpapiere; weder Verk盲ufe noch zus盲tzliche K盲ufe von Stammaktien wurden offengelegt. Abgesehen von dieser routinem盲脽igen Verg眉tung f眉r Direktoren enth盲lt die Meldung keine weiteren wesentlichen Transaktionen oder Eigentums盲nderungen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR鈥擱outine director equity grant; neutral impact, signals standard board alignment.

This Form 4 simply records a scheduled equity award: 2,292 DSUs granted to director Courtney Mather at a reference price of $11.45. DSUs settle after board service ends, so the grant aligns the director鈥檚 incentives with long-term shareholder value but does not represent an open-market purchase. No shares were sold, and the total position now matches the grant amount. Given the modest size and routine nature, the disclosure is not materially impactful for valuation or trading decisions.

Il modulo Form 4 segnala che la direttrice di Chemours Company (CC), Courtney Mather, ha ricevuto in data 30 giugno 2025 un premio di 2.292 unit脿 azionarie differite (DSU). Ogni DSU corrisponde a una azione ordinaria e verr脿 liquidata nel primo mese successivo all'uscita della direttrice dal consiglio. Il premio 猫 stato registrato a un prezzo di riferimento di 11,45 $ per unit脿. Dopo l'assegnazione, Mather possiede direttamente 2.292 titoli derivati; non sono state comunicate vendite o acquisti aggiuntivi di azioni ordinarie. A parte questa consueta remunerazione per il direttore, la comunicazione non riporta altre transazioni rilevanti o variazioni nella propriet脿.

El formulario Form 4 informa que la directora de Chemours Company (CC), Courtney Mather, recibi贸 el 30 de junio de 2025 un premio de 2,292 unidades de acciones diferidas (DSU). Cada DSU equivale a una acci贸n com煤n y se liquidar谩 en el primer mes despu茅s de que la directora deje la junta. El premio se registr贸 a un precio de referencia de $11.45 por unidad. Tras la concesi贸n, Mather posee directamente 2,292 valores derivados; no se revelaron ventas ni compras adicionales de acciones comunes. Aparte de esta compensaci贸n rutinaria para directores, la presentaci贸n no contiene otras transacciones materiales ni cambios en la propiedad.

Form 4 鞝滌稖靹滌棎 霐半ゴ氅� Chemours Company(CC) 鞚挫偓 Courtney Mather電� 2025雲� 6鞗� 30鞚检棎 2,292臧滌潣 鞚挫棸 欤检嫕 雼渼(DSU)毳� 氚涭晿鞀惦媹雼�. 臧� DSU電� 氤错喌欤� 1欤检棎 頃措嫻頃橂┌, 鞚挫偓臧� 鞚挫偓須岇棎靹� 氍茧煬雮� 頉� 觳� 雼棎 鞝曥偘霅╇媹雼�. 鞚� 靸侅潃 雼渼雼� $11.45鞚� 旮办 臧�瓴╈溂搿� 旮半霅橃棃鞀惦媹雼�. 靾橃棳 鞚错泟 Mather電� 歆侅爲 2,292臧滌潣 韺岇儩 歃濌秾鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 氤错喌欤检棎 雽�頃� 毵る弰雮� 於旉皜 毵れ垬電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞚检儊鞝侅澑 鞚挫偓 氤挫儊 鞕胳棎電� 鞝滌稖靹滌棎 雼るジ 欷戩殧頃� 瓯半灅雮� 靻岇湢甓� 氤�霃� 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Le formulaire Form 4 indique que la directrice de Chemours Company (CC), Courtney Mather, a re莽u le 30 juin 2025 une attribution de 2 292 unit茅s d鈥檃ctions diff茅r茅es (DSU). Chaque DSU 茅quivaut 脿 une action ordinaire et sera r茅gl茅e dans le premier mois suivant le d茅part de la directrice du conseil d鈥檃dministration. Cette attribution est enregistr茅e 脿 un prix de r茅f茅rence de 11,45 $ par unit茅. Apr猫s cette attribution, Mather d茅tient directement 2 292 titres d茅riv茅s ; aucune vente ni achat suppl茅mentaire d鈥檃ctions ordinaires n鈥檃 茅t茅 divulgu茅. En dehors de cette r茅mun茅ration habituelle des administrateurs, le d茅p么t ne contient aucune autre transaction significative ni changement de propri茅t茅.

Das Formular Form 4 berichtet, dass die Direktorin von Chemours Company (CC), Courtney Mather, am 30. Juni 2025 mit 2.292 aufgeschobenen Aktienanteilen (DSUs) ausgezeichnet wurde. Jede DSU entspricht einer Stammaktie und wird im ersten Monat nach dem Ausscheiden der Direktorin aus dem Vorstand ausgeglichen. Die Auszeichnung wurde zu einem Referenzpreis von 11,45 $ pro Einheit verbucht. Nach der Zuteilung besitzt Mather direkt 2.292 derivative Wertpapiere; weder Verk盲ufe noch zus盲tzliche K盲ufe von Stammaktien wurden offengelegt. Abgesehen von dieser routinem盲脽igen Verg眉tung f眉r Direktoren enth盲lt die Meldung keine weiteren wesentlichen Transaktionen oder Eigentums盲nderungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ferrante Karen Jean
(Last) (First) (Middle)
C/O COGENT BIOSCIENCES, INC.
275 WYMAN STREET, 3RD FLOOR
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.22 07/01/2025 A 3,314 07/01/2025 07/01/2035 Common Stock 3,314 $0.00(1) 3,314 D
Explanation of Responses:
1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
/s/ Evan D. Kearns, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Chemours (CC) director Courtney Mather receive on 30 June 2025?

He was granted 2,292 deferred stock units, each equal to one share of common stock.

When will Courtney Mather鈥檚 deferred stock units be paid out?

The DSUs become payable in the first month following his termination of service as a director.

What reference price was used for the DSU award?

The filing lists a price of $11.45 per unit.

Did the Form 4 disclose any sales of Chemours stock by the director?

No. The report shows no disposals; only the DSU grant was recorded.

How many Chemours derivative securities does Courtney Mather own after the transaction?

He directly owns 2,292 deferred stock units following the grant.

Is Courtney Mather an officer or a director of Chemours?

The filing designates him as a Director; he is not listed as an officer.
Stock COGT logo
Cogent Biosciences Inc

NASDAQ:COGT

COGT Rankings

#3718 Ranked by Market Cap
N/A Ranked by Dividends
#32 Top Gainer

COGT Latest News

Jul 7, 2025
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
Jun 11, 2025
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
May 29, 2025
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
May 6, 2025
Cogent Biosciences Reports First Quarter 2025 Financial Results
Apr 25, 2025
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

COGT Latest SEC Filings

Jul 7, 2025
[8-K] Cogent Biosciences, Inc. Reports Material Event

COGT Stock Data

834.57M
112.87M
0.16%
108.05%
10.24%
Biotechnology
Pharmaceutical Preparations
United States
WALTHAM